The company’s dual-engine strategy—balancing domestic market penetration with international research partnerships—appears to be yielding results. Revenue from Kangyueda grew by 132% to RMB393 million, bolstered by a 500-person commercial team now reaching over 1,600 hospitals. The drug's inclusion in the 2026 National Essential Medicines List is expected to further drive adoption across primary healthcare markets.

Global operations provided a substantial financial lift as well. Keymed secured RMB224 million in collaboration revenue, largely driven by milestone payments from AstraZeneca. Furthermore, the acquisition of NewCo by Gilead and Lakefront for the development of the CM336 antibody netted the company a US$257 million upfront payment. With cash reserves reaching RMB3.24 billion and an expanded manufacturing capacity of 21,800 litres in Chengdu, the firm is positioning itself to accelerate its next-generation pipeline, including the long-acting TSLP/IL-13 inhibitor CM512.